. Author manuscript; available in PMC: 2018 Sep 1.

Published in final edited form as: J Surg Oncol. 2017 Jun 1;116(3):351–358. doi: 10.1002/jso.24674

Table 1.

Receipt of postoperative CRT in patients with T1 to T2 OPSCC

Characteristic	Overall	Receipt of Postoperative CRT		Multivariable Analysis of Postoperative CRT


	No. (Column %)	No. (Row % Compared With Data Not Shown: No Postoperative CRT)^a	p^b	Adjusted OR (95% C.I.)	p^b
Patients	4833	2120 (43.9%)

Extracapsular spread			p<0.0001
Yes	1208 (25%)	814 (67.4%)		2.75 (2.31 – 3.27)	p<0.0001
No	3625 (75%)	1306 (36%)		1 [Reference]
Margins positive			p<0.0001
Yes	1168 (24.2%)	692 (59.2%)		1.96 (1.66 – 2.32)	p<0.0001
No	3665 (75.8%)	1428 (39%)		1 [Reference]
Nodal classification^c			p<0.0001
N0	1230 (25.5%)	156 (12.7%)		1 [Reference]
N1	921 (19.1%)	368 (40%)		3.67 (2.88 – 4.67)	p<0.0001
N2	2544 (52.6%)	1497 (58.8%)		7.50 (6.02 – 9.35)	p<0.0001
N3	138 (2.9%)	99 (71.7%)		11.85 (7.47 – 18.80)	p<0.0001
Pathologic T-classification^d			p=0.013
T1	2287 (47.3%)	956 (41.8%)		1 [Reference]
T2	2227 (46.1%)	1009 (45.3%)		1.09 (0.95 – 1.27)	p=0.223
T3	208 (4.3%)	95 (45.7%)		1.35 (0.94 – 1.94)	p=0.102
T4	111 (2.3%)	60 (54.1%)		1.09 (0.68 – 1.73)	p=0.732
Age at diagnosis, y			p<0.0001
<50	959 (19.8%)	512 (53.4%)		5.43 (2.89 – 10.21)	p<0.0001
50–64	2682 (55.5%)	1263 (47.1%)		4.44 (2.40 – 8.21)	p<0.0001
65–79	1057 (21.9%)	329 (31.1%)		3.66 (2.00 – 6.71)	p<0.0001
≥80	135 (2.8%)	16 (11.9%)		1 [Reference]
Sex			p<0.0001
Male	3786 (78.3%)	1761 (46.5%)		1.24 (1.04 – 1.48)
Female	1047 (21.7%)	359 (34.3%)		1 [Reference]	p=0.017
Race			p<0.0001
White	4429 (91.6%)	1984 (44.8%)		1 [Reference]
Black	268 (5.5%)	79 (29.5%)		0.63 (0.45 – 0.88)	p=0.007
Other	136 (2.8%)	57 (41.9%)		0.94 (0.62 – 1.44)	p=0.776
Insurance status			p<0.0001
Private	3310 (68.5%)	1623 (49%)		1.54 (1.23 – 1.93)	p<0.0001
Uninsured	187 (3.9%)	93 (49.7%)		1.76 (1.16 – 2.67)	p=0.008
Government^e	1336 (27.6%)	404 (30.2%)		1 [Reference]
Charlson-Deyo Comorbidity Index			p<0.0001
0	3908 (80.9%)	1769 (45.3%)		1 [Reference]
1	754 (15.6%)	293 (38.9%)		0.91 (0.74 – 1.11)	p=0.330
2	171 (3.5%)	58 (33.9%)		0.71 (0.48 – 1.07)	p=0.106
Year diagnosed			p<0.0001
2004	225 (4.7%)	76 (33.8%)		1 [Reference]
2005	235 (4.9%)	112 (47.7%)		2.07 (1.33 – 3.23)	p=0.001
2006	299 (6.2%)	149 (49.8%)		2.39 (1.56 – 3.65)	p<0.0001
2007	306 (6.3%)	175 (57.2%)		3.52 (2.30 – 5.38)	p<0.0001
2008	480 (9.9%)	285 (59.4%)		3.37 (2.28 – 4.99)	p<0.0001
2009	569 (11.8%)	313 (55%)		3.30 (2.25 – 4.84)	p<0.0001
2010	580 (12%)	235 (40.5%)		2.33 (1.58 – 3.44)	p<0.0001
2011	647 (13.4%)	267 (41.3%)		2.19 (1.50 – 3.21)	p<0.0001
2012	719 (14.9%)	265 (36.9%)		1.89 (1.30 – 2.75)	p=0.001
2013	773 (16%)	243 (31.4%)		1.46 (1.00 – 2.13)	p=0.051
Facility type			p<0.0001
Academic/ NCI CCC	2848 (58.9%)	1083 (38.0%)		1 [Reference]
Community	1985 (41.1%)	1037 (52.2%)		1.49 (1.18 – 1.87)	p=0.001
Hospital volume			p<0.0001
1–10 pts	1360 (28.1%)	704 (51.8%)		1.41 (0.99 – 2.01)	p=0.055
11–20 pts	847 (17.5%)	359 (42.4%)		0.99 (0.70 – 1.42)	p=0.973
21–50 pts	1107 (22.9%)	454 (41%)		1.02 (0.72 – 1.45)	p=0.911
>50 pts	1519 (31.4%)	603 (39.7%)		1 [Reference]

“No postoperative CRT” includes patients who underwent surgery alone, or surgery followed by radiation. For ease of visualization, this column of data is not shown in the table.

p-values in bold type are <.05

Nodal stage defined as pathologic N-stage if available, otherwise clinical stage.

Pathologic T stage used because all patients in table had primary surgery; pathologic stage related to use of adjuvant therapy

Medicare and Medicaid